Literature DB >> 2938614

Stereoselective interaction between the R enantiomer of warfarin and cimetidine.

I A Choonara, S Cholerton, B P Haynes, A M Breckenridge, B K Park.   

Abstract

The stereoselectivity of the pharmacokinetic interaction between warfarin and cimetidine was investigated in eight healthy volunteers. The warfarin enantiomers were given separately as single doses (15 mg) alone and during chronic administration of cimetidine (1 g day-1). Cimetidine did not interact with S warfarin but there was an interaction with the R enantiomer of warfarin. Cimetidine caused a significant increase in the mean plasma half-life of R warfarin (from 47.8 h to 57.8 h) and a significant decrease in its mean plasma clearance (from 2.3 to 1.7 ml h-1 kg-1) (P less than 0.02). Administration of a pharmacological dose of vitamin K1 together with the enantiomers of warfarin was necessary clinically and resulted in elevation of vitamin K1 2,3-epoxide concentrations, which were similar in each case.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2938614      PMCID: PMC1400859          DOI: 10.1111/j.1365-2125.1986.tb05190.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  22 in total

1.  Differential effect of the enantiomers of phenprocoumon and warfarin on the vitamin K1-epoxide/vitamin K1 ratio in rat plasma.

Authors:  W Schmidt; D Beermann; F Oesch; E Jähnchen
Journal:  J Pharm Pharmacol       Date:  1979-07       Impact factor: 3.765

2.  The stereoselective interaction of warfarin and metronidazole in man.

Authors:  R A O'Reilly
Journal:  N Engl J Med       Date:  1976-08-12       Impact factor: 91.245

3.  Effect of warfarin on the metabolism of phylloquinone (vitamin K1):dose-response relationships in man.

Authors:  M J Shearer; A McBurney; A M Breckenridge; P Barkhan
Journal:  Clin Sci Mol Med       Date:  1977-06

4.  Studies on the optical enantiomorphs of warfarin in man.

Authors:  R A O'Reilly
Journal:  Clin Pharmacol Ther       Date:  1974-08       Impact factor: 6.875

5.  Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man.

Authors:  A Breckenridge; M Orme; H Wesseling; R J Lewis; R Gibbons
Journal:  Clin Pharmacol Ther       Date:  1974-04       Impact factor: 6.875

6.  Pharmacokinetics of warfarin enantiomers: a search for intrasubject correlations.

Authors:  L B Wingard; R A O'Reilly; G Levy
Journal:  Clin Pharmacol Ther       Date:  1978-02       Impact factor: 6.875

Review 7.  Metabolism of vitamin K and prothrombin synthesis: anticoagulants and the vitamin K--epoxide cycle.

Authors:  R G Bell
Journal:  Fed Proc       Date:  1978-10

8.  Changes in phylloquinone epoxidase activity related to prothrombin synthesis and microsomal clotting activity in the rat.

Authors:  A K Willingham; J T Matschiner
Journal:  Biochem J       Date:  1974-06       Impact factor: 3.857

9.  Vitamin K1 metabolism in relation to pharmacodynamic response in anticoagulated patients.

Authors:  I A Choonara; A K Scott; B P Haynes; S Cholerton; A M Breckenridge; B K Park
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

10.  Cimetidine: interaction with oral anticoagulants in man.

Authors:  M J Serlin; R G Sibeon; S Mossman; A M Breckenridge; J R Williams; J L Atwood; J M Willoughby
Journal:  Lancet       Date:  1979-08-18       Impact factor: 79.321

View more
  17 in total

Review 1.  Progress in clinical pharmacology over the last 20 years.

Authors:  Michel Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  2003-05       Impact factor: 4.335

Review 2.  Clinical relevance of cimetidine drug interactions.

Authors:  A F Shinn
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

Review 3.  Haematological adverse effects of histamine H2-receptor antagonists.

Authors:  J P Aymard; B Aymard; P Netter; B Bannwarth; P Trechot; F Streiff
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

Review 4.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

5.  Enantiomers of warfarin and vitamin K1 metabolism.

Authors:  I A Choonara; B P Haynes; S Cholerton; A M Breckenridge; B K Park
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

Review 6.  Ranitidine versus cimetidine. A comparison of their potential to cause clinically important drug interactions.

Authors:  S R Smith; M J Kendall
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

7.  Further insight into the stereoselective interaction between warfarin and cimetidine in man.

Authors:  I Niopas; S Toon; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

Review 8.  Pharmacokinetic interactions of cimetidine 1987.

Authors:  A Somogyi; M Muirhead
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

Review 9.  Stereoisomers and drug toxicity. The value of single stereoisomer therapy.

Authors:  A K Scott
Journal:  Drug Saf       Date:  1993-02       Impact factor: 5.606

10.  Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man.

Authors:  S Toon; K J Hopkins; F M Garstang; M Rowland
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.